K2B Therapeutics is a biotech company developing targeted cancer therapies using proprietary protein-drug conjugates designed for precise drug delivery.

‍

‍

The Challenge

‍

K2B began its scientific work at LabCentral, an incubator in Cambridge with a model designed to support companies for a limited period. As the company continued to grow, its needs began to evolve beyond the traditional incubator model. K2B was looking for a more flexible, capital-efficient workspace that could accommodate its team while supporting the company’s next stage of growth.

‍

‍

The Solution

‍

K2B considered several options, including other shared lab operators and building out its own space, before ultimately choosing Labshares. Labshares is particularly well suited for growing biotechs moving beyond the incubator stage, offering the infrastructure and support they need as they scale. K2B also attended a recent Labshares panel featuring biotech VCs, which showcased the broader community and resources available to Labshares members. Jay Kim, CEO of K2B, said the event “sealed the deal” for K2B’s decision to join Labshares.

‍

K2B moved into a private lab suite at Labshares’ new location, 66 Galen in Watertown, with dedicated office space right outside the lab that provides the team with a more collaborative setup.

‍

In addition, K2B valued the easier commute, free parking, and access to a community of more mature biotech companies. Labshares events also offer additional opportunities for the team to connect with the broader biotech ecosystem, including investors.

‍

‍

Results

‍

K2B was fully operational in its new lab less than two weeks after moving into Labshares, allowing the team to quickly get back to advancing its science.

‍

“I notice that we now have better communication. We’re all together, and that’s been a huge benefit to our company. We’re very comfortable here,” said Jay Kim, CEO of K2B.

‍

Joe Nabhan, CSO at K2B, also highlighted the responsiveness and day-to-day support from the Labshares team since moving in.

‍

“The team’s responsiveness in supporting the shared equipment and lab infrastructure has been exemplary. We were particularly excited when we learned that the team was very receptive to our requests for adding specific instruments and equipment.”

‍

Unlike the LabCentral model, Labshares has no time limit on how long companies can stay. K2B can continue growing its team and expanding its footprint within Labshares, avoiding the cost and disruption of another move while staying focused on its science and key milestones.

‍